Analysis reveals 1-year overall survival of 48% in patients with relapsed PMBL after CAR-T, highlighting checkpoint inhibitors as a potential treatment option.
Key Points
Study aims to describe outcomes and treatment patterns of PMBL patients after CAR-T therapy failure.
Included patients with progression post anti-CD19 CAR-T cell therapy from the DESCAR-T registry.
Evaluated overall survival and progression-free survival after treatment failure.
Salvage therapies were assessed, including checkpoint inhibitors and chemotherapy.
1-year overall survival was 48.1% with a median overall survival of 11.7 months.
41% of treated patients achieved complete response post salvage therapy.
Checkpoint inhibitors had a complete response rate of 64% compared to lower rates for other treatments.